Adjuvant interleukin-12 gene therapy for the management of colorectal liver metastases
- 8 October 2004
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 11 (12) , 782-789
- https://doi.org/10.1038/sj.cgt.7700760
Abstract
In humans, no efficient treatment exists not only against multifocal liver metastases (LM) but also against recurrent microscopic liver metastases within the liver remnant following curative liver resection. Furthermore, in nonmultifocal LM, partial liver resection could be performed, but in more than 50% of the patients, tumor recurrence within liver remnant is observed, partly due to the growth of dormant cancer cells in the setting of postoperative host immune dysfunction. We investigated the therapeutic potential of interleukin-12 (IL-12) immuno-gene therapies in these experimental models under total vascular exclusion (TVE) of the liver. In rats with multiple LM of DHDK12 colon cancer cells, we observed a significant reduction in tumor volume after retroviral-mediated gene transfer of either herpes simplex virus thymidine kinase (HSV1-TK) and ganciclovir (GCV) administration, or IL-12. Combined treatment with HSV1-TK/GCV and IL-12 resulted in improved tumor volume reduction and even survival. In rats with recurrent microscopic DHDK12 LM established after partial liver resection, we observed significantly decreased recurrent tumor volumes and increased survival after retroviral-mediated IL-12 gene transfer. In both settings, immunohistological analysis revealed that IL-12 immuno-gene therapy was accompanied by an infiltration of CD8+ T lymphocytes within the tumors. Altogether, our results suggest that IL-12 adjuvant gene therapy could improve the management of patients with either resectable or unresectable LM.Keywords
This publication has 27 references indexed in Scilit:
- Intratumoral Delivery of Adenovirus-Mediated Interleukin-12 Gene in Mice with Metastatic Cancer in the LiverHuman Gene Therapy, 2002
- Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver TumorsAnnals of Surgery, 2000
- Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinomaCancer Gene Therapy, 2000
- Gene Transfer to Liver Cancer Cells of B7-1 Plus Interleukin 12 Changes Immunoeffector Mechanisms and Suppresses Helper T Cell Type 1 Cytokine Production Induced by Interleukin 12 AloneHuman Gene Therapy, 2000
- Hepatic Arterial Infusion of Chemotherapy after Resection of Hepatic Metastases from Colorectal CancerNew England Journal of Medicine, 1999
- Regional treatment of hepatic micrometastasis by adenovirus vector-mediated delivery of interleukin-2 and interleukin-12 cDNAs to the hepatic parenchymaCancer Gene Therapy, 1999
- A “Distant” Bystander Effect of Suicide Gene Therapy: Regression of Nontransduced Tumors Together with a Distant Transduced TumorHuman Gene Therapy, 1997
- Clinical Trials: IL-12 Deaths: Explanation and a PuzzleScience, 1995
- The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cellsCancer Letters, 1995
- Dormant liver metastases: an experimental studyBritish Journal of Surgery, 1992